抄録検索

検索結果

PAGE : [1]      <<      175   |   176   |   177   |   178   |   179   |   180   |   181      >>      [184]
検索結果 178/184ページ目を表示(合計:1836件)

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-11

Lymph node status guides taxane-based escalating and de-escalating chemotherapy in patients with early triple negative breast cancer

Speaker)Sanxing Guo:1、Suzhi Zhang:2、Na Wang:3、Yujie He:4、Xingya Li:1
1:Oncology Department, The First Affiliated Hospital of Zhengzhou University, China、2:Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, China、3:Department of Radiotherapy, The First Affiliated Hospital of Zhengzhou University, China、4:Rheumatology and Immunology Department, The First Affiliated Hospital of Zhengzhou University, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-12

The combination of NVP-BEZ235 and endostatin exerts synergistic anticancer activity against triple-negative breast cancer in vitro and in vivo

Speaker)Xiaoshan Wang:1、Xiao Zhang:2、Fanghua Li:3
1:Cancer Center, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China、2:Department of Breast Surgery, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China、3:Department of Pathology, Sichuan Provincial People Hospital, University of Electronic Science and Technology of China, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-13

Fulvestrant 500mg versus Exemestane in postmenopausal Metastatic Breast Cancer (MBC) resistant to adjuvant Non-steroidal Aromatase Inhibitors (NSAI) in clinical practice

Speaker)Yizhao Xie:1、Biyun Wang:1、Yannan Zhao:1、Chengcheng Gong:1、Yi Li:1、Xichun Hu:1、Jian Zhang:1、Leiping Wang:1
1:Medical Oncology, Fudan University Shanghai Cancer Center, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-14

Cost-effectiveness analysis of bevacizumab plus paclitaxel versus bevacizumab plus capecitabine for HER2-negative metastatic breast cancer

Speaker)Qiuji Wu:1、Qiu Li:1
1:Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, China

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-15

Concordance assessment of IBM Watson for oncology with MDT in patients with breast cancer

Speaker)Junnan Xu:1,2、Tao Sun:1,2
1:Department of Medical Onocolgy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, China、2:Key Laboratory of Liaoning Breast Cancer Research, China

抄録

第56回・2018年・横浜

FACO Poster Session

抄録

第56回・2018年・横浜

FACO Poster Session

抄録

第56回・2018年・横浜

FACO Poster Session

抄録

第56回・2018年・横浜

FACO Poster Session

FACO Poster Session 2
FACO Poster Session 2

演題番号 : FP2-19

Postoperative micropapillary lung adenocarcinoma patients have higher rates of vascular cancer thrombi, bronchial invasion and positive ALK fusion protein

Speaker)Shaomei Li:1、Cuicui Zhang:1、Qiming Wang:1
1:Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou University, China

抄録

第56回・2018年・横浜

FACO Poster Session

抄録
PAGE : [1]      <<      175   |   176   |   177   |   178   |   179   |   180   |   181      >>      [184]